曹佳彬;魏敬双;

• 1:华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室

摘要(Abstract)：

肿瘤通过刺激免疫系统的抑制受体改变原有免疫反应,进行免疫逃逸。通过阻断T细胞抑制受体,阻断肿瘤的发生,为抗肿瘤免疫提供了潜在的治疗方法。PD-1(programmed death-1)是T细胞抑制受体,在T细胞功能性紊乱时持续表达,其可作为停止信号在肿瘤中限制T细胞的效应功能。阻断PD-1信号可有效帮助衰竭T细胞,促进抗肿瘤免疫应答。PD-1抗体在癌症治疗及免疫刺激中具有重要作用,本文就PD-1及其配体、PD-1/PD-Ls信号通路以及PD-1抗体在肿瘤治疗中的应用作一综述。

关键词(KeyWords)： PD-1;抗体;肿瘤;T细胞;检验点

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 曹佳彬;魏敬双;

DOI: 10.13200/j.cnki.cjb.000414

参考文献(References)：

• [1]Brahmer JR,Drake CG,Wollner I,et al.Phase I study of single-agent anti-programmed death-1(MDX-1106)in refractory solid tumors:safety,clinical activity,pharmacodynamics,and immunologic correlates[J].J Clin Oncol,2010,28(19):3167-3175.
• [2]Liu J,Hamrouni A,Wolowiec D,et al.Plasma cells from multiple myeloma patients express B7-H1(PD-L1)and increase expression after stimulation with IFN-{γ}and TLR ligands via a MyD88-,TRAF6-,and MEK-dependent pathway[J].Blood,2007,110(1):296-304.
• [3]Ishida Y,Agata Y,Shibahara K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
• [4]Nishimura H,Nose M,Hiai H,et al.Development of lupuslike autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J].Immunity,1999,11(2):141-151.
• [5]Wang SY,Sun Y,Jin H,et al.Role of PD-1/PD-Ls signal pathway in tumor immunity escape and its treatment[J].Med Recapit,2013,19(11):1973-1975.(in Chinese)王水英,孙宇,金惠,等.PD-1/PD-Ls信号通路在肿瘤免疫逃逸及其治疗中的作用[J].医学综述,2013,19(11):1973-1975.
• [6]Fife BT,Guleria I,Gubbels Bupp M,et al.Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway[J].J Exp Med,2006,203(12):2737-2747.
• [7]Francisco LM,Sage PT,Sharpe AH.The PD-1 pathway in tolerance and autoimmunity[J].Immunol Rev,2010,236(6):219-242.
• [8]Riley JL.PD-1 signaling in primary T cells[J].Immunol Rev,2009,229(1):114-125.
• [9]Barber DL,Wherry EJ,Masopust D,et al.Restoring function in exhausted CD8 T cells during chronic viral infection[J].Nature,2006,439(7077):682-687.
• [10]Keir ME,Butte MJ,Freeman GJ,et al.PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26:677-704.
• [11]Prosser ME,Brown CE,Shami AF,et al.Tumor PD-L1 costimulates primary human CD8+cytotoxic T cells modified to express a PD1:CD28 chimeric receptor[J].Mol Immunol,2012,51(3-4):263-272.
• [12]Kearl TJ,Jing WQ,Gershan GA,et al.Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma[J].J Immunol,2013,190(11):5620-5628.
• [13]Achleiner A,Clark ME,Bienzle D.T-regulatory cells infected with feline immunodeficiency virus up-regulate programmed death-1(PD-1)[J].Vet Immunol Immunopathol,2011,143(3-4):307-313.
• [14]Hamanishi J,Mandai M,Iwasaki M,et al.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer[J].Proc Natl Acad Sci USA,2007,104(9):3360-3365.
• [15]Good-Jacobson KL,Szumilas CG,Chen L,et al.PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells[J].Nat Immunol,2010,11(6):535-542.
• [16]Paterson AM,Brown KE,Keir ME,et al.The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo[J].J Immunol,2011,187(3):1097-1105.
• [17]Jin HT,Ahmed R,Okazaki T.Role of PD-1 in regulating Tcell immunity[J].Curr Top Microbiol Immunol,2011,350(1):17-37.
• [18]Wu YL,Liang J,Zhang W,et al.Immunotherapies:the blockade of inhibitory signals[J].Int J Biol Sci,2012,8(10):1420-1430.
• [19]Flies DB,Sandler BJ,Sznol M,et al.Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy[J].Yale J Biol Med,2011,84(4):409-421.
• [20]Weber J.Immune checkpoint proteins:a new therapeutic paradigm for cancer-preclinical background:CTLA-4 and PD-1blockade[J].Semin Oncol,2010,37(5):430-439.
• [21]Wherry EJ.T cell exhaustion[J].Nat Immunol,2011,12(6):492-499.
• [22]Pentcheva-Hoang T,Corse E,Allison JP.Negative regulators of T-cell activation:Potential targets for therapeutic intervention in cancer,autoimmune disease,and persistent infections[J].Immunol Rev,2009,229(1):67-87.
• [23]Yokosuka T,Takamatsu M,Kobayashi-Imanishi W,et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J].J Exp Med,2012,209(6):1201-1217.
• [24]Latchman Y,Wood CR,Chernove T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.
• [25]Brunner MC,Chambers CA,Chan FK,et al.CTLA-4-mediated inhibition of early events of T cell proliferation[J].J Immunol,1999,162(10):5813-5820.
• [26]Quigley M,Pereyra F,Nilsson B,et al.Transcription analysis of HIV-specific CD8+T cells shows that PD-1 inhibits T cell function by upregulating BATF[J].Nat Med,2010,16(10):1147-1151.
• [27]Brahmer JR,Tykodi SS,Chow LQ,et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J].N Engl J Med,2012,366(26):2455-2465.
• [28]Swann JB,Vesely MD,Silva A,et al.Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis[J].Proc Natl Acad Sci USA,2008,105(2):652-656.
• [29]Matsuzaki J,Gnjatic S,Mhawech-Fauceglia P,et al.Tumorinfiltrating NY-ESO-1-specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer[J].Proc Natl Acad Sci USA,2010,107(17):7875-7880.
• [30]Ahmadzadeh M,Johnson LA,Heemskerk B,et al.Tumor antigen-specificCD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J].Blood,2009,114(8):1537-1544.
• [31]Quezada SA,Peggs KS.Exploiting CTLA-4,PD-1 and PD-L1to reactivate the host immune response against cancer[J].Br J Cancer,2013,108(8):1560-1565.
• [32]Simeone E,Ascierto PA.Immunomodulating antibodies in the treatment of metastatic melanoma:The experience with antiCTLA-4,anti-CD137 and anti-PD1[J].J Immunotoxicol,2012,9(3):241-247.
• [33]Postow MA,Harding J,Wolchok JD.Targeting immune checkpoints:releasing the restraints on anti-tumor immunity for patients with melanoma[J].Cancer J,2012,18(2):153-159.
• [34]Sheridan C.Cautious optimism surrounds early clinical data for PD-1 blocker[J].Nat Biotechnol,2012,30(8):729-733.
• [35]Hamid O,Robert C,Daud A,et al.Safety and tumor responses with lambrolizumab(anti-PD-1)in melanoma[J].N Engl J Med,2013,369(2):134-144.
• [36]Zitvogel L,Kroemer G.Targeting PD-1/PD-L1 interactions for cancer immunotherapy[J].Oncoimmunol,2012,1(8):1223-1225.
• [37]104th AACR Annual Conference,Abs LB-193[C].Washington DC,2013.
• [38]Curran MA,Montalvo W,Yagita H,et al.PD-1 and CTLA-4combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J].Proc Natl Acad Sci USA,2010,107(9):4275-4280.